Edap TMSFOCL +1.91%53 PS Ratio is 1.82 as of Jun. 24, 2026, which is 21% below its 10-year median of 2.29. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 118 Medical Distribution companies, Edap TMS ranks worse than 86.44% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Edap TMS's share price is $5.075.
Edap TMS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.79. Hence, Edap TMS's PS Ratio for today is 1.82.
Warning Sign:
Edap TMS SA stock PS Ratio (=1.78) is close to 1-year high of 1.78.
The historical rank and industry rank for Edap TMS's PS Ratio or its related term are showing as below:
FOCL'
s PS Ratio Range Over the Past 10 Years
Min: 0.46 Med: 2.29 Max: 7.1
Current: 1.81
During the past 13 years, Edap TMS's highest PS Ratio was 7.10. The lowest was 0.46. And the median was 2.29.
FOCL's PS Ratio is ranked worse than 86.44% of 118
companies
in the Medical Distribution industry
Industry Median: 0.44
vs FOCL: 1.81
During the past 12 months, the average Revenue per Share Growth Rate of Edap TMS was 5.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.40% per year.
During the past 13 years, Edap TMS's highest 3-Year average Revenue per Share Growth Rate was 11.40% per year. The lowest was -16.80% per year. And the median was 0.10% per year.
Back to Basics: PS Ratio
Edap TMS (NAS:FOCL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Edap TMS PS Ratio Related Terms
Edap TMS PS Ratio Historical Data
* Premium members only.
The historical data trend for Edap TMS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Edap TMS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Edap TMS's Share Price of today is $5.075. Edap TMS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Edap TMS (FOCL) has a PS Ratio of 1.82 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Edap TMS and its competitors. This is 21% below median its historical median of 2.29. Over the past decade, Edap TMS's PS Ratio has ranged from 0.46 to 7.10. According to the industry distribution chart, Edap TMS ranks #102 out of 118 companies in the Medical Distribution industry, placing it in the top 86.4%.
Is Edap TMS's PS Ratio too high?
Edap TMS's current PS Ratio of 1.82 is 21% below median its 10-year median of 2.29. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 7.10. The Medical Distribution industry median PS Ratio is 0.44. Edap TMS's value of 1.82 is 313.6% above this industry median. Based on the distribution chart, Edap TMS ranks #102 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's PS Ratio compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #102 out of 118 companies for PS Ratio. This places Edap TMS in the lower half of its industry. The industry median PS Ratio is 0.44. Edap TMS's value of 1.82 is 313.6% above this benchmark. Historically, Edap TMS's own PS Ratio has ranged from 0.46 to 7.10 over the past decade. While the company's 10-year median is 2.29 vs. the industry median of 0.44, Edap TMS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.44, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edap TMS's current PS Ratio of 1.82 is 313.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current PS Ratio is 1.82, which is 21% below median its own 10-year median of 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current PS Ratio is 1.82, which is 21% below median its 10-year median of 2.29 and 313.6% above the Medical Distribution industry median of 0.44. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Edap TMS (FOCL), the current PS Ratio is 1.82 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52.
GuruFocus considers Edap TMS to be Modestly Overvalued.
Key valuation signals for FOCL:
PS Ratio: 1.82 (21% below median its 10-year median of 2.29)
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
Industry Position: 313.6% above the Medical Distribution median (#102 of 118)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
53GF Score
Get the complete analysis for FOCL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
